OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting

OnCusp reported a 62% objective response rate (13/21, including 3 complete responses) for CUSP06 at 4.0 mg/kg in its Phase 1b platinum-resistant ovarian cancer study; 81 of 86 patients were evaluable for efficacy as of September 23, 2026. The study also reported a 53% ORR (16/30) among patients previously treated with mirvetuximab soravtansine. Safety findings included no ocular toxicity and one pneumonitis case among 86 patients; response and durability data remain immature, and the FDA has granted CUSP06 Fast Track designation.

Analysis

The signal is clinically interesting but not yet a commercial read-through. The apparent dose pattern is non-monotonic: the 4.0 mg/kg cohort outperformed both G-CSF-supported cohorts, so the dataset does not establish that higher exposure or prophylactic G-CSF improves the therapeutic window. Small cohorts and open-label assessment leave meaningful room for patient-mix and measurement effects. Crucially, the 10.5-month median duration of response is from Phase 1a HGSOC—not the Phase 1b efficacy cohorts—so durability cannot yet validate the headline response rate.

The post-mirvetuximab activity is the most strategically relevant result: if it persists with follow-up, CUSP06 could address a later-line population not adequately served by the existing sequence. But one response-rate snapshot does not prove non-cross-resistance or displace current therapy; comparative duration, progression-free survival, and toxicity are the needed evidence. A single pneumonitis event is too little exposure to support a safety advantage over other ADCs.

Near term, expect attention on dose selection and data maturity rather than an immediate change in treatment standards. Over 1–3 months, the key catalyst is fuller conference/clinical disclosure; over 6–18 months, pivotal-trial design, enrollment pace, and financing or partnering terms determine whether the signal becomes investable. OnCusp is not mapped to a public ticker in the supplied data, so there is no clean direct equity expression. The contrarian risk is that investors anchor on the 62% cohort and underweight durability, tolerability over longer exposure, and the execution burden of a pivotal program.

Key Decisions for Investors

• No direct position on this release alone: the supplied company mapping has no ticker, and the result is early, small-cohort evidence rather than a registrational readout.
• Set a catalyst watch for disclosure of Phase 1b duration of response, progression-free survival, follow-up duration, and response-evaluable patient characteristics—especially in the post-mirvetuximab subgroup.
• Treat 4.0 mg/kg dose selection as unresolved. Reassess only after dose-level safety, dose intensity, and efficacy are reported with longer follow-up; the current data do not show a clear benefit from G-CSF-supported or higher-dose cohorts.
• Falsify the differentiated-activity thesis if post-mirvetuximab responses prove short-lived, Phase 1b durability materially trails the Phase 1a benchmark, or cumulative hematologic toxicity forces substantial dose reductions or weakens planned pivotal dosing.